2-Hexyl cyanoacrylate (neuracryl M) embolization of cerebral arteriovenous malformations

Ricardo J Komotar, Evan R. Ransom, David A. Wilson, E. Sander Connolly, Sean D. Lavine, Philip M. Meyers

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

OBJECTIVE: Neuracryl M is a newly designed liquid embolic agent. In an attempt to verify the safety and efficacy of neuracryl M, we participated in the PROVASIS Trial, a pilot study using this agent in the preoperative treatment of cerebral arteriovenous malformations (AVMs). Because the trial was prematurely terminated by the sponsoring company because of financial considerations, we now present our data as a single center series. METHODS: Between November 2002 and December 2003, six patients were enrolled in the PROVASIS trial at our institution, and four of these patients were randomized to treatment with neuracryl M. The patients were a 30-year-old man with a right frontal lobe AVM, a 20-year-old man with a right cerebellar AVM, a 26-year-old woman with a midline cerebellar AVM, and a 47-year-old man with a left parietotemporal lobe AVM. All patients underwent AVM embolization with neuracryl M, followed by definitive treatment, either open surgery or radiosurgery. RESULTS: In each case, there were no permanent complications, and blood loss was minimal. Follow-up imaging demonstrated either complete AVM obliteration (open surgery) or substantial diminution in AVM size (radiosurgery). CONCLUSION: Our data provide preliminary evidence supporting the thesis that neuracryl M is a safe and effective liquid embolic agent for the preoperative embolization of cerebral AVMs. Larger trials and continued experience using this novel liquid embolic agent are warranted.

Original languageEnglish
JournalNeurosurgery
Volume59
Issue number4 SUPPL. 2
DOIs
StatePublished - Oct 1 2006
Externally publishedYes

Fingerprint

Cyanoacrylates
Intracranial Arteriovenous Malformations
Arteriovenous Malformations
Radiosurgery
Frontal Lobe
Therapeutics
Safety

Keywords

  • 2-Hexyl Cyanoacrylate
  • Arteriovenous
  • Embolization
  • Malformations
  • Neuracryl M

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

2-Hexyl cyanoacrylate (neuracryl M) embolization of cerebral arteriovenous malformations. / Komotar, Ricardo J; Ransom, Evan R.; Wilson, David A.; Connolly, E. Sander; Lavine, Sean D.; Meyers, Philip M.

In: Neurosurgery, Vol. 59, No. 4 SUPPL. 2, 01.10.2006.

Research output: Contribution to journalArticle

Komotar, Ricardo J ; Ransom, Evan R. ; Wilson, David A. ; Connolly, E. Sander ; Lavine, Sean D. ; Meyers, Philip M. / 2-Hexyl cyanoacrylate (neuracryl M) embolization of cerebral arteriovenous malformations. In: Neurosurgery. 2006 ; Vol. 59, No. 4 SUPPL. 2.
@article{571ab12bd9c4439f8db297e41d695045,
title = "2-Hexyl cyanoacrylate (neuracryl M) embolization of cerebral arteriovenous malformations",
abstract = "OBJECTIVE: Neuracryl M is a newly designed liquid embolic agent. In an attempt to verify the safety and efficacy of neuracryl M, we participated in the PROVASIS Trial, a pilot study using this agent in the preoperative treatment of cerebral arteriovenous malformations (AVMs). Because the trial was prematurely terminated by the sponsoring company because of financial considerations, we now present our data as a single center series. METHODS: Between November 2002 and December 2003, six patients were enrolled in the PROVASIS trial at our institution, and four of these patients were randomized to treatment with neuracryl M. The patients were a 30-year-old man with a right frontal lobe AVM, a 20-year-old man with a right cerebellar AVM, a 26-year-old woman with a midline cerebellar AVM, and a 47-year-old man with a left parietotemporal lobe AVM. All patients underwent AVM embolization with neuracryl M, followed by definitive treatment, either open surgery or radiosurgery. RESULTS: In each case, there were no permanent complications, and blood loss was minimal. Follow-up imaging demonstrated either complete AVM obliteration (open surgery) or substantial diminution in AVM size (radiosurgery). CONCLUSION: Our data provide preliminary evidence supporting the thesis that neuracryl M is a safe and effective liquid embolic agent for the preoperative embolization of cerebral AVMs. Larger trials and continued experience using this novel liquid embolic agent are warranted.",
keywords = "2-Hexyl Cyanoacrylate, Arteriovenous, Embolization, Malformations, Neuracryl M",
author = "Komotar, {Ricardo J} and Ransom, {Evan R.} and Wilson, {David A.} and Connolly, {E. Sander} and Lavine, {Sean D.} and Meyers, {Philip M.}",
year = "2006",
month = "10",
day = "1",
doi = "10.1227/01.NEU.0000222654.27895.FA",
language = "English",
volume = "59",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "4 SUPPL. 2",

}

TY - JOUR

T1 - 2-Hexyl cyanoacrylate (neuracryl M) embolization of cerebral arteriovenous malformations

AU - Komotar, Ricardo J

AU - Ransom, Evan R.

AU - Wilson, David A.

AU - Connolly, E. Sander

AU - Lavine, Sean D.

AU - Meyers, Philip M.

PY - 2006/10/1

Y1 - 2006/10/1

N2 - OBJECTIVE: Neuracryl M is a newly designed liquid embolic agent. In an attempt to verify the safety and efficacy of neuracryl M, we participated in the PROVASIS Trial, a pilot study using this agent in the preoperative treatment of cerebral arteriovenous malformations (AVMs). Because the trial was prematurely terminated by the sponsoring company because of financial considerations, we now present our data as a single center series. METHODS: Between November 2002 and December 2003, six patients were enrolled in the PROVASIS trial at our institution, and four of these patients were randomized to treatment with neuracryl M. The patients were a 30-year-old man with a right frontal lobe AVM, a 20-year-old man with a right cerebellar AVM, a 26-year-old woman with a midline cerebellar AVM, and a 47-year-old man with a left parietotemporal lobe AVM. All patients underwent AVM embolization with neuracryl M, followed by definitive treatment, either open surgery or radiosurgery. RESULTS: In each case, there were no permanent complications, and blood loss was minimal. Follow-up imaging demonstrated either complete AVM obliteration (open surgery) or substantial diminution in AVM size (radiosurgery). CONCLUSION: Our data provide preliminary evidence supporting the thesis that neuracryl M is a safe and effective liquid embolic agent for the preoperative embolization of cerebral AVMs. Larger trials and continued experience using this novel liquid embolic agent are warranted.

AB - OBJECTIVE: Neuracryl M is a newly designed liquid embolic agent. In an attempt to verify the safety and efficacy of neuracryl M, we participated in the PROVASIS Trial, a pilot study using this agent in the preoperative treatment of cerebral arteriovenous malformations (AVMs). Because the trial was prematurely terminated by the sponsoring company because of financial considerations, we now present our data as a single center series. METHODS: Between November 2002 and December 2003, six patients were enrolled in the PROVASIS trial at our institution, and four of these patients were randomized to treatment with neuracryl M. The patients were a 30-year-old man with a right frontal lobe AVM, a 20-year-old man with a right cerebellar AVM, a 26-year-old woman with a midline cerebellar AVM, and a 47-year-old man with a left parietotemporal lobe AVM. All patients underwent AVM embolization with neuracryl M, followed by definitive treatment, either open surgery or radiosurgery. RESULTS: In each case, there were no permanent complications, and blood loss was minimal. Follow-up imaging demonstrated either complete AVM obliteration (open surgery) or substantial diminution in AVM size (radiosurgery). CONCLUSION: Our data provide preliminary evidence supporting the thesis that neuracryl M is a safe and effective liquid embolic agent for the preoperative embolization of cerebral AVMs. Larger trials and continued experience using this novel liquid embolic agent are warranted.

KW - 2-Hexyl Cyanoacrylate

KW - Arteriovenous

KW - Embolization

KW - Malformations

KW - Neuracryl M

UR - http://www.scopus.com/inward/record.url?scp=33750050542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750050542&partnerID=8YFLogxK

U2 - 10.1227/01.NEU.0000222654.27895.FA

DO - 10.1227/01.NEU.0000222654.27895.FA

M3 - Article

C2 - 17041518

AN - SCOPUS:33750050542

VL - 59

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 4 SUPPL. 2

ER -